|
1
|
Hoeffel Rosa da I, Resner de Moraes M and
Lovato B: Derma-tology in Public Health EnvironmentsA Comprehensive
Textbook. Bonamigo RR and Dornelles SIT: Springer; Switzerland:
2018
|
|
2
|
Young JW and Shear NH: Cutaneous drug
reactions in the elderly. Drugs Aging. 34:655–672. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balakirski G and Merk HF: Cutaneous
allergic drug reactions: Update on pathophysiology, diagnostic
procedures and differential diagnosic. Cutan Ocul Toxicol.
36:307–316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chopra D, Sharma V, Kapoor R and Dwivedi
S: An observational study of cutaneous adverse drug reactions in a
teaching hospital. Int J Clin Pharm. 37:996–999. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ding WY, Lee CK and Choon SE: Cutaneous
adverse drug reactions seen in a tertiary hospital in Johor,
Malaysia. Int J Dermatol. 49:834–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nandha R, Gupta A and Hashmi A: Cutaneous
adverse drug reactions in a tertiary care teaching hospital: A
North Indian perspective. Int J Appl Basic Med Res. 1:50–53. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wick JY: Drug-induced rash: Nuisance or
threat? Consult Pharm. 28:160–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Redwood AJ, Pavlos RK, White KD and
Phillips EJ: HLAs: Key regulators of T-cell-mediated drug
hypersensitivity. HLA. 91:3–16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Demoly P, Adkinson NF, Brockow K, Castells
M, Chiriac AM, Greenberger PA, Khan DA, Lang DM, Park HS, Pichler
W, et al: International Consensus on drug allergy. Allergy.
69:420–437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gomes E, Cardoso MF, Praça F, Gomes L,
Mariño E and Demoly P: Self-reported drug allergy in a general
adult Portuguese population. Clin Exp Allergy. 34:1597–1601. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jurado-Escobar R, Perkins JR,
García-Martín E, Isidoro-García M, Doña I, Torres MJ and
Cornejo-García JA: Update on the genetic basis of drug
hypersensitivity reactions. J Investig Allergol Clin Immunol.
27:336–345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bircher AJ and Scherer Hofmeier K: Drug
hypersensitivity reactions: Inconsistency in the use of the
classification of immediate and nonimmediate reactions. J Allergy
Clin Immunol. 129:263–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen CB, Abe R, Pan RY, Wang CW, Hung SI,
Tsai YG and Chung WH: An updated review of the molecular mechanisms
in drug hypersensitivity. J Immunol Res. 2018:64316942018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
European Commission: A Guideline on
summary of product characteristics (SmPC), 2009. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf
|
|
15
|
Arguello B, Salgado TM and
Fernandez-Llimos F: Assessing the information in the Summaries of
Product Characteristics for the use of medicines in pregnancy and
lactation. Br J Clin Pharmacol. 79:537–544. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vromans L, Doyle G, Petak-Opel S, Rödiger
A, Röttgermann M, Schlüssel E and Stetter E: Shaping medicinal
product information: A before and after study exploring physicians'
perspectives on the summary of product characteristics. BMJ Open.
3:e0030332013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arguello B and Fernandez-Llimos F:
Clinical pharmacology information in summaries of product
characteristics and package inserts. Clin Pharmacol Ther.
82:566–571. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rougemont M, Ulrich S, Hiemke C, Corruble
E and Baumann P: French summaries of product characteristics:
Content in relation to therapeutic monitoring of psychotropic
drugs. Fundam Clin Pharmacol. 24:377–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ulrich S, Hiemke C, Laux G,
Müller-Oerlinghausen B, Havemann-Reinecke U, Riederer P, Zernig G
and Baumann P; TDM group of the Arbeitsgemeinschaft
Neuropsychopharma-kologie und Pharmakopsychiatrie (AGNP), : Value
and actuality of the prescription information for therapeutic drug
monitoring of psychopharmaceuticals: A comparison with the
medico-scientific evidence. Pharmacopsychiatry. 40:121–127. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Salgado TM, Arguello B, Martinez-Martinez
F, Benrimoj SI and Fernandez-Llimos F: Clinical relevance of
information in the Summaries of Product Characteristics for dose
adjustment in renal impairment. Eur J Clin Pharmacol. 69:1973–1979.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salgado TM, Arguello B, Martinez-Martinez
F, Benrimoj SI and Fernandez-Llimos F: Lack of harmonisation in the
classification of renal impairment in European Summaries of Product
Characteristics. Intern Med J. 45:686–687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bergk V, Haefeli WE, Gasse C, Brenner H
and Martin-Facklam M: Information deficits in the summary of
product characteristics preclude an optimal management of drug
interactions: A comparison with evidence from the literature. Eur J
Clin Pharmacol. 61:327–335. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
San Miguel MT, Martínez JA and Vargas E:
Food-drug interactions in the summary of product characteristics of
proprietary medicinal products. Eur J Clin Pharmacol. 61:77–83.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hallersten A, Fürst W and Mezzasalma R:
Physicians prefer greater detail in the biosimilar label (SmPC) -
Results of a survey across seven European countries. Regul Toxicol
Pharmacol. 77:275–281. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hoetzenecker W, Nägeli M, Mehra ET, Jensen
AN, Saulite I, Schmid-Grendelmeier P, Guenova E, Cozzio A and
French LE: Adverse cutaneous drug eruptions: Current understanding.
Semin Immunopathol. 38:75–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Happel CS: Rash diagnostics: An update on
the diagnosis of allergic rashes. Curr Opin Pediatr. 29:371–378.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
National Clinical Guideline Centre, . Drug
Allergy: Diagnosis and Management of Drug Allergy in Adults,
Children and Young People. https://www.ncbi.nlm.nih.gov/pubmed/25340226May
20–2019
|
|
28
|
Bircher AJ: Drug hypersensitivityChemical
Immunology and Allergy. Bergmann KC and Ring J: 100. Karger; Basel:
pp. 120–131. 2014, View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haasbach E, Hartmayer C, Hettler A,
Sarnecka A, Wulle U, Ehrhardt C, Ludwig S and Planz O: Antiviral
activity of Ladania067, an extract from wild black currant leaves
against influenza A virus in vitro and in vivo. Front Microbiol.
5:1712014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Romano A, Valluzzi RL, Caruso C,
Maggioletti M and Gaeta F: Non-immediate cutaneous reactions to
beta-lactams: Approach to diagnosis. Curr Allergy Asthma Rep.
17:232017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jones RT, Evans W, Mersfelder TL and
Kavanaugh K: Rare Red Rashes: A case report of
levetiracetam-induced cutaneous reaction and review of the
literature. Am J Ther. 23:e944–e946. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bahrani E, Nunneley CE, Hsu S and Kass JS:
Cutaneous adverse effects of neurologic medications. CNS Drugs.
30:245–267. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Golian E, Kwong BY, Swetter SM and
Pugliese SB: Cutaneous complications of targeted melanoma therapy.
Curr Treat Options Oncol. 17:572016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zulian F, Martini G, Gobber D, Plebani M,
Zacchello F and Manners P: Triamcinolone acetonide and hexacetonide
intra-articular treatment of symmetrical joints in juvenile
idiopathic arthritis: A double-blind trial. Rheumatology (Oxford).
43:1288112912004. View Article : Google Scholar
|
|
35
|
R Development Core Team, . R: A Language
and Environment for Statistical ComputingR Foundation for
Statistical Computing; Vienna: 2017, https://www.R-project.orgMay 20–2019
|
|
36
|
Nasu S, Suzuki H, Shiroyama T, Tanaka A,
Iwata K, Ryota N, Ueda Y, Takata SO, Masuhiro K, Morita S, et al:
Skin rash can be a useful marker for afatinib efficacy. Anticancer
Res. 38:1783–1788. 2018.PubMed/NCBI
|
|
37
|
Hichert V, Scholl C, Steffens M, Paul T,
Schumann C, Rüdiger S, Boeck S, Heinemann V, Kächele V, Seufferlein
T, et al: Predictive blood plasma biomarkers for EGFR
inhibitor-induced skin rash. Oncotarget. 8:35193–35204. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
van Doorn R and van Zuuren EJ: Epidermal
growth factor receptor inhibitor-associated rash prevented by oral
tetracyclines. Br J Dermatol. 175:1135–1136. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ding PN, Lord SJ, Gebski V, Links M, Bray
V, Gralla RJ, Yang JC and Lee CK: Risk of treatment-related
toxicities from EGFR tyrosine kinase inhibitors: A meta-analysis of
clinical trials of gefitinib, erlotinib, and afatinib in advanced
EGFR-mutated non-small cell lung cancer. J Thorac Oncol.
12:633–643. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Boccellino M, Quagliuolo L, Alaia C,
Grimaldi A, Addeo R, Nicoletti GF, Kast RE and Caraglia M: The
strange connection between epidermal growth factor receptor
tyrosine kinase inhibitors and dapsone: From rash mitigation to the
increase in anti-tumor activity. Curr Med Res Opin. 32:1839–1848.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tischer B, Huber R, Kraemer M and
Lacouture ME: Dermatologic events from EGFR inhibitors: The issue
of the missing patient voice. Support Care Cancer. 25:651–660.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brown TA: Gene cloning and DNA analysis:
an introduction6th. Wiley-Blackwell; Oxford, Hoboken, NJ: 2010
|
|
43
|
Wilcox MH, Gerding DN, Poxton IR, Kelly C,
Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, et al:
MODIFY I and MODIFY II Investigators: Bezlotoxumab for prevention
of recurrent clostridium difficile infection. N Engl J Med.
376:305–317. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu L: Antibody glycosylation and its
impact on the pharmacokinetics and pharmacodynamics of monoclonal
antibodies and Fc-fusion proteins. J Pharm Sci. 104:1866–1884.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Acetazolamide 250 mg tablets. Summary of
Product Characteristics. 2019, https://www.medicines.org.uk/emc/product/2785/smpcMay
20–2019
|
|
46
|
Ogoshi M, Yamada Y and Tani M: Acute
generalized exanthematic pustulosis induced by cefaclor and
acetazolamide. Dermatology. 184:142–144. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Spring M: Skin eruptions following the use
of diamox. Ann Allergy. 14:41–43. 1956.PubMed/NCBI
|
|
48
|
Ogasawara K, Tomitsuka N, Kobayashi M,
Komoribayashi N, Fukuda T, Saitoh H, Inoue T and Ogawa A:
Stevens-Johnson syndrome associated with intravenous acetazolamide
administration for evaluation of cerebrovascular reactivity. Case
report. Neurol Med Chir (Tokyo). 46:161–163. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Her Y, Kil MS, Park JH, Kim CW and Kim SS:
Stevens-Johnson syndrome induced by acetazolamide. J Dermatol.
38:272–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
ClinicalTrials.gov, . 24 Studies found
for: Acetazolamide/Recruiting, Not yet recruiting. Studies. 2018,
https://clinicaltrials.gov/ct2/results?May
5–2018
|
|
51
|
Carboplatin 10 mg/ml concentrate for
solution for infusion. Summary of Product Characteristics. 2012,
https://www.medicines.org.uk/emc/product/6005/smpcMay
5–2018
|
|
52
|
Carboplatin 10 mg/ml Intravenous infusion.
Summary of Product Characteristics. 2017, https://www.medicines.org.uk/emc/product/3787/smpcMay
5–2018
|
|
53
|
Digoxin 250 micrograms/ml Solution for
injection. Summary of Product Characteristics. 2017, https://www.medicines.org.uk/emc/product/5290/smpcMay
5–2018
|
|
54
|
Lanoxin 125 Tablets. Summary of Product
Characteristics. 2018, https://www.medicines.org.uk/emc/product/5461May
5–2018
|
|
55
|
Digoxin Tablets BP 125 micrograms. Summary
of Product Characteristics. 2014, https://www.medicines.org.uk/emc/product/5773/smpcMay
5–2018
|
|
56
|
Tecfidera 120 mg and 240 mg
gastro-resistant hard capsules. Summary of Product Characteristics.
2018, https://www.medicines.org.uk/emc/product/5256May
5–2018
|
|
57
|
Skilarence 120 mg Gastro-resistant
Tablets. Summary of Product Characteristics. 2017, https://www.medicines.org.uk/emc/product/7480May
5–2018
|
|
58
|
Doxorubicin Solution for injection.
Summary of product characteristics. 2016, https://www.medicines.org.uk/emc/product/6184May
5–2018
|
|
59
|
Doxorubicin (Myocet) 50 mg powder,
dispersion and solvent for concentrate for dispersion for infusion.
Summary of Product Characteristics. 2015, https://www.medicines.org.uk/emc/product/5378May
5–2018
|
|
60
|
Doxorubicin 2 mg/ml Concentrate for
Solution for infusion. Summary of Product Characteristics. 2016,
https://www.medicines.org.uk/emc/product/6112/smpcMay
5–2018
|
|
61
|
MHRA. Public Assessment Report.
Decentralized procedure. Doxorubicin 2 mg/ml Concentrate for
Solution for infusion (doxorubicin hydrochloride).
UK/H/1347/001/DC. UK Licence numbers: PL20075/0109. 2010,
https://www.medicines.org.uk/emc/product/8443/smpcMay
5–2018
|
|
62
|
Aurobeverine MR 200 mg modified-release
capsules, hard. Summary of Product Characteristics. 2017,
https://www.medicines.org.uk/emc/product/8994May
5–2018
|
|
63
|
Pourmoghaddas Z, Saneian H, Roohafza H and
Gholamrezaei A: Mebeverine for pediatric functional abdominal pain:
A randomized, placebo-controlled trial. BioMed Res Int.
2014:1910262014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lee KJ, Kim NY, Kwon JK, Huh KC, Lee OY,
Lee JS, Choi SC, Sohn CI, Myung SJ, Park HJ, et al: Efficacy of
ramosetron in the treatment of male patients with irritable bowel
syndrome with diarrhea: A multicenter, randomized clinical trial,
compared with mebeverine. Neurogastroenterol Motil. 23:1098–1104.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Jones RH, Holtmann G, Rodrigo L,
Ehsanullah RS, Crompton PM, Jacques LA and Mills JG: Alosetron
relieves pain and improves bowel function compared with mebeverine
in female nonconstipated irritable bowel syndrome patients. Aliment
Pharmacol Ther. 13:1419–1427. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Van Outryve M, Mayeur S, Meeus MA,
Rosillon D, Hendrickx B and Ceuppens M: A double-blind crossover
comparison study of the safety and efficacy of mebeverine with
mebeverine sustained release in the treatment of irritable bowel
syndrome. J Clin Pharm Ther. 20:277–282. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Rahman MZ, Ahmed DS, Mahmuduzzaman M,
Rahman MA, Chowdhury MS, Barua R and Ishaque SM: Comparative
efficacy and safety of trimebutine versus mebeverine in the
treatment of irritable bowel syndrome. Mymensingh Med J.
23:105–113. 2014.PubMed/NCBI
|
|
68
|
Gilbody JS, Fletcher CP, Hughes IW and
Kidman SP: Comparison of two different formulations of mebeverine
hydrochloride in irritable bowel syndrome. Int J Clin Pract.
54:461–464. 2000.PubMed/NCBI
|
|
69
|
Directive 2001/83/EC of the European
Parliament and of the Council of 6 November 2001 on the Community
Code relating to Medicinal Products for Human Use, as amended.
Official Journal L. 311:67–128. 2004 May 5–2018
|
|
70
|
Atracurium 10 mg/ml Solution for injection
or infusion. Summary of Product Characteristics. 2014, https://www.medicines.org.uk/emc/searchMay
5–2018
|
|
71
|
Atracurium 10 mg/ml Solution for
injection/infusion. Summary of Product Characteristics. 2013,
https://www.medicines.org.uk/emc/product/5729May
5–2018
|
|
72
|
Atracurium Besilate 10 mg/ml Solution for
injection - ampoule. Summary of Product Characteristics. 2017,
https://www.medicines.org.uk/emc/searchMay
5–2018
|
|
73
|
Aptivus 100 mg/ml oral solution. Summary
of Product Characteristics. 2017, https://www.medicines.org.uk/emc/product/4451May
5–2018
|
